Cureshank Community News: August 2026

Written By Julia Manis

Each month, we're proud to share the latest resources, participation opportunities, and advancements in science. This month’s edition is packed with updates that reflect the momentum building in our community.

Last month, a landmark study confirmed what our community has long suspected: Phelan-McDermid syndrome is far more prevalent than previously estimated. With thousands of individuals likely undiagnosed, the urgent need for expanded genetic testing awareness and investment in PMS research has never been clearer.

This month, we're proud to share updates that reflect the momentum building in our community. Our CSO Ralf Schmid explores why having multiple drug programs in development simultaneously is a strength and what it means for the future of PMS treatment. We're also sharing updates from Genetic Testing Action Day 2026, ongoing research participation opportunities, and our new PMS Prevalence Tracker.

As always, get the full story here.

Julia Manis
Next

Why Multiple Drug Programs for Phelan-McDermid Syndrome need to be Moving Forward at Once